Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th - Conference Call to Follow
MWN-AI** Summary
Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced it will release its financial results for the fourth quarter and full year of 2025 after market close on March 5, 2026. Following the release, the company's management will host a conference call at 4:30 p.m. ET to discuss the results and provide insights into business developments. This event marks a significant opportunity for investors and analysts to gain a deeper understanding of Profound’s financial performance and strategic initiatives.
Profound Medical is a commercial-stage medical device company focused on developing and marketing innovative interventional MRI (iMRI) procedures. Its flagship product, TULSA-PRO®, integrates advanced technologies including real-time MRI and AI-enhanced planning for its proprietary TULSA Procedure™, which offers a non-invasive treatment option for various prostate conditions. The TULSA Procedure aims to effectively treat patients across the prostate disease spectrum, including those with low to high-risk prostate cancer, benign prostatic hyperplasia (BPH), and individuals requiring salvage therapy for radio-recurrent localized prostate cancer. With its real-time MR guidance, the procedure emphasizes precision, aiming to preserve patients' urinary continence and sexual function while treating targeted prostate tissue.
In addition to TULSA-PRO, Profound is also commercializing Sonalleve®, a therapeutic platform approved for treating conditions such as uterine fibroids and bone metastases pain palliation. With ongoing exploration into new treatment markets, Profound Medical is cementing its position as a leader in innovative medical technologies. Investors and interested parties are encouraged to register for the conference call, which will also be available on the company’s website for later viewing.
MWN-AI** Analysis
As Profound Medical Corp. prepares to release its fourth quarter and full year 2025 financial results on March 5, 2026, investors should approach the announcement with both optimism and caution. The innovative nature of Profound's medical device offerings, particularly the TULSA-PRO and Sonalleve technologies, positions the company favorably in a growing market, catering to significant medical needs in prostate and uterine health.
The TULSA-PRO, which utilizes advanced MRI guidance and ultrasound technology, offers a compelling value proposition as a non-invasive treatment for prostate disorders. This could drive increased adoption rates among healthcare providers, especially as the market shifts toward procedures that prioritize patient safety and rapid recovery times. The conference call following the earnings release will be critical, as management is expected to provide insights on sales performance, patient outcomes, and market expansion strategies.
Investors should closely monitor operational metrics such as revenue growth from TULSA-PRO and Sonalleve, expected profit margins, and any updates on regulatory approvals or new clinical applications. With FDA clearance and CE marking already in place, Profound is positioned well for international expansion, which could further bolster its financial health.
Additionally, keep an eye out for broader trends in the medical device sector, particularly the increasing demand for minimally invasive procedures. Assessing competition and market share will also be essential, as the landscape becomes crowded with emerging technologies.
In summary, while the upcoming financial results may reveal short-term volatility in stock price, the longer-term outlook for Profound Medical appears bullish, contingent upon successful market penetration and continued investment in R&D. Investors should consider their risk appetite and monitor progress post-announcement closely.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.
Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.
Fourth Quarter and Full Year 2025 Results Conference Call Details:
Date: Thursday, March 5, 2026
Time: 4:30 p.m. ET
Live Call Registration: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2
The call will also be broadcast live and archived on the Company's website in the Investors section here.
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
FAQ**
What key financial metrics should investors look for in Profound Medical Corp. PROF's fourth quarter and full year 2025 results announcement on March 5, 2026?
How has Profound Medical Corp. PROF expanded its market reach for the TULSA-PRO system since its last financial report, and what are the management's projections moving forward?
In what ways is Profound Medical Corp. PROF planning to enhance the clinical applications of the Sonalleve platform, especially in cancer therapy, as discussed in the upcoming conference call?
What potential challenges or regulatory hurdles might Profound Medical Corp. PROF face in further commercializing TULSA-PRO and Sonalleve technologies, and how is management addressing them?
**MWN-AI FAQ is based on asking OpenAI questions about Profound Medical Corp. (TSXC: PRN:CC).
NASDAQ: PRN:CC
PRN:CC Trading
0.45% G/L:
$11.28 Last:
9,800 Volume:
$11.23 Open:
